NGNE
NeurogeneยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
NGNE Profile
Neurogene Inc.
A biopharmaceutical company using protein design technology to develop immunotherapies
Biological Technology
12/26/2003
03/07/2014
NASDAQ Stock Exchange
107
12-31
Common stock
535 W 24th Street, 5th Floor, New York, NY 10011
--
Neurogene Inc., formerly known as 6175813 Canada Inc. (6175813 Canada Inc.). The company was incorporated on December 26, 2003 under the Canadian Business Corporations Act. Neurogene's mission is to treat devastating neurological diseases to improve the lives of patients and families affected by these rare diseases. Neurogene is developing new methods and treatments to address the limitations of traditional gene therapy in central nervous system diseases. This includes choosing a delivery method to maximize distribution to the target organization and designing the product to maximize potency and purity to achieve optimized efficacy and safety. Neurogene's new proprietary EXACT transgenic regulatory platform technology allows delivery of therapeutic levels while limiting transgenic toxicity associated with conventional gene therapy. Neurogene has built a state-of-the-art gene therapy manufacturing facility in Houston, Texas.
